• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Zillion partners with Dexcom on CGM integration

July 7, 2022 By Sean Whooley

Zillion and Dexcom logosZillion announced today that it partnered with Dexcom (Nasdaq:DXCM) to integrate its CGM technology with Zillion’s digital health platform.

Needham, Massachusetts-based Zillion will connect Dexcom’s continuous glucose monitoring (CGM) platform with its digital health offering for the RestoreHealth program, enhancing RestoreHealth for employer and health system patients.

“Type 2 diabetes continues to be a growing health problem. At Zillion, our goal is to develop programs to improve individual health outcomes, as well as reduce medical expenses,” Zillion President and CEO Cheryl Morrison Deutsch said in a news release. “We’re excited to partner with Dexcom to provide patients with the data they need to take control of their health and experience real improvements that help them live happier and healthier lives.”

RestoreHealth features personalized, actionable support for employees that address health issues before they escalate. The company’s Zillion platform, a content-agnostic platform enabling organizations to deliver their programs through a tailored technology and services solution.

Zillion CMO Dr. Cate Collings said that Dexcom’s CGM represents a technological improvement that helps RestoreHealth members and coaches proactively manage real-time health data to allow for adjustments to their plan of care.

According to Dr. Cate Collings, Chief Medical Officer for Zillion, CGM represents a technological improvement that helps RestoreHealth members and coaches proactively manage real-time health data to allow for adjustments to the plan of care.

“We have seen metabolic disease factor reduction with RestoreHealth,” Collings said. “In some cases, we have been able to successfully decrease disease incidence. We expect to see significant enhancement to these results with this partnership.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom, Zillion

IN CASE YOU MISSED IT

  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS